And although individuals with HNF1A-MODY are more sensitive to sulfonylureas than those with type 2 diabetes [17], their beta cell response to sulfonylureas is similar to that in control individuals without diabetes [15, 18], rendering it unlikely that the MODY variant directly affects sulfonylurea sensitivity. The gene discussed is HNF1A; the disease is diabetes mellitus.